Product Description
Quetiapine (Seroquel), a dibenzothiazepine derivative, is an atypical antipsychotic with demonstrated efficacy in acute schizophrenia. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/14871161/)
Mechanisms of Action: 5-HT1A Antagonist,5-HT2 Antagonist,D2 Antagonist,H1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Bipolar Disorder | Depressive Disorder | Schizophrenia | Bipolar Disorder | Depressive Disorder | Depressive Disorder, Major | Schizophrenia
Known Adverse Events: Tachycardia | Abdominal Pain | Dizziness | Lethargy | Pain Unspecified | Pharyngitis | Constipation | Dyspepsia | Weight Gain | Dysarthria
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Bulgaria, Canada, Czech Republic, Denmark, France, Germany, Hungary, Japan, Poland, Russia, Slovakia, Spain, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Insomnia
Phase 2: Depressive Disorder|Depressive Disorder, Major
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MEL-QUE | P3 |
Recruiting |
Insomnia |
2029-02-28 |
|
| NCT04521478 | P2 |
Completed |
Depressive Disorder, Major |
2024-01-10 |
32% |
| NCT04521478 | P2 |
Completed |
Depressive Disorder, Major |
2024-01-10 |
32% |
| JapicCTI-205406 | P2 |
Planned |
Depressive Disorder, Major |
2022-08-31 |
|
| 2019-004264-21 | P2 |
Active, not recruiting |
Depressive Disorder |
2022-04-12 |